Overview
Celularity is a clinical and commercial-stage regenerative medicine company specializing in off-the-shelf allogeneic cell therapies derived from postpartum placental tissue. The company develops multiple therapeutic platforms including mesenchymal-like adherent stromal cells (MLASCs), natural killer (NK) cells, engineered T cells with CAR modifications, and exosome-based therapies, alongside a portfolio of advanced biomaterial products. Celularity's therapeutic focus spans age-related diseases, cancer, infectious diseases, and degenerative conditions, with the overarching mission of addressing fundamental aging mechanisms including cellular senescence, chronic inflammation, and tissue degeneration.